Mar 01

Phase I STTR grant supporting ProFine(R) study

MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine in enhancing standard prostate cancer therapy.